Elsevier

The Lancet Neurology

Volume 10, Issue 8, August 2011, Pages 721-733
The Lancet Neurology

Review
The monoamine neurotransmitter disorders: an expanding range of neurological syndromes

https://doi.org/10.1016/S1474-4422(11)70141-7Get rights and content

Summary

The monoamine neurotransmitter disorders consist of a rapidly expanding heterogeneous group of neurological syndromes characterised by primary and secondary defects in the biosynthesis degradation, or transport of dopamine, norepinephrine, epinephrine, and serotonin. Disease onset can occur any time from infancy onwards. Clinical presentation depends on the pattern and severity of neurotransmitter abnormalities, and is predominated by neurological features (encephalopathy, epilepsy, and pyramidal and extrapyramidal motor disorders) that are primarily attributed to deficiency of cerebral dopamine, serotonin, or both. Many neurotransmitter disorders mimic the phenotype of other neurological disorders (eg, cerebral palsy, hypoxic ischaemic encephalopathy, paroxysmal disorders, inherited metabolic diseases, and genetic dystonic or parkinsonian syndromes) and are, therefore, frequently misdiagnosed. Early clinical suspicion and appropriate investigations, including analysis of neurotransmitters in CSF, are essential for accurate clinical diagnosis. Treatment strategies focus on the correction of monoamine deficiency by replacement of monoamine precursors, the use of monoamine analogues, inhibition of monoamine degradation, and addition of enzyme cofactors to promote monoamine production.

Introduction

Brain neurotransmission is an essential process for neuronal differentiation and growth, as well as for the development of interneuronal communication and neuronal circuitry.1 Inherited abnormalities in neurotransmitter synthesis, breakdown, and transport represent an expanding group of neurometabolic syndromes with important therapeutic implications.2 Symptoms are determined by the type and severity of the disorder and are dominated by neurological features, including developmental delay, pyramidal and extrapyramidal motor disorders, epilepsy, autonomic dysfunction, and neuropsychiatric symptoms. Overall, the clinical phenotype mimics that of many other neurological disorders and, therefore, misdiagnosis or diagnostic delay are common. Onset can occur at any age but is most frequently in infancy or early childhood.

Neurotransmitter disorders are due to aberrant metabolism or transport of the biogenic amines, glycine, vitamin B6, GABA, and glutamic acid.2, 3, 4 The biogenic amines are a functionally important group of brain neurotransmitters5 and consist of the catecholamines (dopamine, norepinephrine, and epinephrine) and serotonin. Dopamine and serotonin have key roles in the brain, including the control of locomotion, mood, and behaviour.

In this Review, we focus on the monoamine neurotransmitter disorders that lead to depletion in availability of dopamine, serotonin, or both. We aim to clearly define the clinical, biochemical, and molecular genetic features of disorders of pterin, dopamine, and serotonin metabolism (figure 1, table). A practical guide to specialist diagnostic investigations and a comprehensive therapeutic approach to each monoamine neurotransmitter disorder will also be discussed.

Section snippets

Role of dopamine and serotonin

Metabolism of dopamine and serotonin in the brain are postulated to be closely linked at biochemical and physiological levels (figure 2).8, 9 Dopamine was thought to be a purely intermediary substrate in the biosynthesis of norepinephrine and epinephrine, until the 1950s, when Carlsson and colleagues10 discovered that dopamine was present in high concentrations in the rat corpus striatum. Administration of reserpine, which blocked the vesicular monoamine transporter, led to dopamine depletion

Neurological investigations

The diagnosis of a monoamine neurotransmitter disorder is established on the basis of clinical history, physical examination, biochemical investigations, enzyme analysis (for some disorders), and analysis of genetic mutations (figure 3).28 The specific pattern of neurotransmitter metabolites can be indicative of a particular neurotransmitter disorder (figure 3).

Autosomal dominant GTPCH deficiency

Autosomal dominant GTPCH deficiency (Online Mendelian Inheritance in Man mutation number [OMIM] #128230; also known as Segawa disease, DYT 5a, and dopa-responsive dystonia) was first clinically reported in the 1970s. Segawa and colleagues40, 41 described a syndrome of extrapyramidal basal ganglia features with a striking response to levodopa and, in one adult with a 43-year clinical course, hereditary progressive dystonia with notable diurnal fluctuation.41

Age of disease onset is generally

Disorders of selective serotonin deficiency

A distinct group of patients present with motor disorders associated with an isolated deacrease in 5-HIAA production. Naumann and colleagues84 have reported a series of adult patients with idiopathic adult-onset dystonia in which 5-HIAA levels were significantly lower than those in controls. 5-HIAA concentrations might also be reduced in other adult neurological disorders, such as cerebellar tremor, neuropsychiatric disorders, and Alzheimer's disease. The observation that patients with dystonia

Secondary neurotransmitter disorders

Neurotransmitters abnormalities indicative of dopamine or serotonin depletion are becoming increasingly recognised as secondary phenomena in several neurological disorders. Concentrations of HVA and 5-HIAA in CSF in such patients are mostly within the range deemed abnormal for primary neurotransmitter disorders, but generally do not reach the lowest levels.

A secondary reduction in HVA is reported in perinatal asphyxia, disorders of folate metabolism, phenylketonuria, Lesch-Nyhan disease,

Conclusions

The monoamine neurotransmitter disorders are an expanding group of neurological syndromes, many of which present in infancy and early childhood (table). They are important to recognise because they are frequently misdiagnosed and many show a good clinical response to treatment. Increased clinical awareness, reliable and reproducible biochemical testing, and advances in molecular genetic testing have improved delineation of the phenotypic spectrum of such disorders. Analysis of neurotransmitters

Search strategy and selection criteria

We searched PubMed for articles published from January, 1964, until May, 2011, in English, with the terms “neurotransmitter”, “monoamine”, “dopamine”, “serotonin”, “HVA”, “HIAA”, “5-HIAA”, “dopa responsive dystonia”, “autosomal dominant GTP cyclohydrolase 1 deficiency”, “autosomal recessive GTP cyclohydrolase 1 deficiency”, “sepiapterin reductase deficiency”, “dihydropteridine reductase deficiency”, “6-pyruvoyltetrahydropterin synthase deficiency”, “tyrosine hydroxylase deficiency”, “aromatic

References (90)

  • I Marín-Valencia et al.

    Biochemical diagnosis of dopaminergic disturbances in paediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines

    Clin Biochem

    (2008)
  • E Garelis et al.

    Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies

    Brain Res

    (1974)
  • WL Yeung et al.

    Galactorrhea—a strong clinical clue towards the diagnosis of neurotransmitter disease

    Brain Dev

    (2006)
  • R Saunders-Pullman et al.

    Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test

    Mol Genet Metab

    (2004)
  • M Segawa

    Hereditary progressive dystonia with marked diurnal fluctuation

    Brain Dev

    (2011)
  • GA Horvath et al.

    Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms

    Mol Genet Metab

    (2008)
  • L Jäggi et al.

    Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency

    Mol Genet Metab

    (2008)
  • GF Allen et al.

    A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency

    Mol Genet Metab

    (2009)
  • MA Kurian et al.

    Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study

    Lancet Neurol

    (2011)
  • JC Van Der Heyden et al.

    Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism

    Eur J Paediatr Neurol

    (2003)
  • A Garcia-Cazorla et al.

    Mitochondrial diseases mimicking neurotransmitter defects

    Mitochondrion

    (2008)
  • JC Jen et al.

    Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures

    Neurology

    (2005)
  • N Blau et al.

    Disorders of tetrahydrobiopterin and related biogenic amines

  • RR Gainetdinov et al.

    Monoamine transporters: from genes to behavior

    Annu Rev Pharmacol Toxicol

    (2003)
  • K Hyland et al.

    Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population

    Pediatr Res

    (1993)
  • A Carlsson et al.

    On the presence of 3-hydroxytyramine in brain

    Science

    (1958)
  • A Carlsson

    The occurrence, distribution and physiological role of catecholamines in the nervous system

    Pharmacol Rev

    (1959)
  • A Dahlstroem et al.

    Evidence for the existence of monoamine-containing neurons in the central nervous system. I. demonstration of monoamines in the cell bodies of brain stem neurons

    Acta Physiol Scand Suppl

    (1964)
  • GE Hoffman et al.

    Monoamine distribution in primate brain. III. Catecholamine-containing varicosities in the hypothalamus of Macaca mulatta

    Am J Anat

    (1976)
  • GE Torres et al.

    Plasma membrane monoamine transporters: structure, regulation and function

    Nat Rev Neurosci

    (2003)
  • A Carlsson

    Perspectives on the discovery of central monoaminergic neurotransmission

    Annu Rev Neurosci

    (1987)
  • A Carlsson

    A paradigm shift in brain research

    Science

    (2001)
  • P Greengard

    The neurobiology of slow synaptic transmission

    Science

    (2001)
  • EC Azmitian

    The serotonin-producing neurons of the midbrain median and dorsal raphe nuclei

    Handb Psychopharmacol

    (1978)
  • ME Molliver

    Serotonergic neuronal systems: what their anatomic organization tells us about function

    J Clin Psychopharmacol

    (1987)
  • LM Adams et al.

    Possible involvement of brain noradrenergic neurons in dystonia

    Adv Neurol

    (1988)
  • RJ Leo

    Movement disorders associated with the serotonin selective reuptake inhibitors

    J Clin Psychiatry

    (1996)
  • GF Hoffmann et al.

    Cerebrospinal fluid investigations for neurometabolic disorders

    Neuropediatrics

    (1998)
  • H McConnell et al.

    CSF as a reflection of cerebral metabolism

  • C Bräutigam et al.

    Neurotransmitter metabolites in CSF: an external quality control scheme

    J Inherit Metab Dis

    (2002)
  • B Assmann et al.

    Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia

    Ann Neurol

    (2003)
  • N Longo

    Disorders of biopterin metabolism

    J Inherit Metab Dis

    (2009)
  • PL Pearl et al.

    Diagnosis and treatment of neurotransmitter disorders

    Curr Treat Options Neurol

    (2006)
  • O Bandmann et al.

    The phenylalanine loading test in the differential diagnosis of dystonia

    Neurology

    (2003)
  • T Opladen et al.

    Phenylalanine loading in pediatric patients with dopa-responsive dystonia: revised test protocol and pediatric cutoff values

    J Inherit Metab Dis

    (2010)
  • Cited by (0)

    View full text